32 results on '"Kunal Gala"'
Search Results
2. Evaluation of an Objective MRI-Based Tumor Regression Grade (mrTRG) Score and a Subjective Likert Score for Assessing Treatment Response in Locally Advanced Rectal Cancers—A Retrospective Study
- Author
-
Aparna N. Katdare, Akshay D. Baheti, Sayali Y. Pangarkar, Kunal A. Mistry, Suman K. Ankathi, Purvi D. Haria, Amit J. Choudhari, Amrita Guha, Kunal Gala, Nitin Shetty, Suyash Kulkarni, Mukta Ramadwar, and Munita Bal
- Subjects
Likert ,MRI ,rectal cancer ,TRG ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Purpose: Magnetic resonance imaging (MRI) with the help of MRI-based tumor regression grade (mrTRG) score has been used as a tool to predict pathological tumor regression grade (pTRG) in patients of rectal cancer post-neoadjuvant chemoradiation. Our study aims to evaluate the ability of MRI in assessing treatment response comparing an objective mrTRG score and a subjective Likert score, with a focus on the ability to predict pathologic complete response (pCR).
- Published
- 2024
- Full Text
- View/download PDF
3. Safety and Efficacy of Vacuum-Assisted Breast Biopsies under Ultrasound and Stereotactic Guidance
- Author
-
Palak Bhavesh Thakkar Popat, Aashna Karbhari, Nitin Shetty, Kunal Gala, Purvi Haria, Aparna Katdare, Sonal Chauhan, Vani Parmar, Nita Nair, Shalaka Joshi, Sangeeta Desai, Tanuja Shet, Asawari Patil, Ayushi Sahay, Meenakshi Thakur, Rajendra Badwe, and Suyash Kulkarni
- Subjects
breast ,intervention ,biopsy ,vacuum-assisted biopsy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Purpose To evaluate the safety and efficacy of vacuum-assisted breast biopsy (VABB) under ultrasound and stereotactic guidance.
- Published
- 2023
- Full Text
- View/download PDF
4. Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India
- Author
-
Jyoti Bajpai, Pritesh Munot, Kishore Kota, Gaurav Gupta, Kunal Gala, Aashish Gulia, Bharat Rekhi, Nehal Khanna, Nitin Shetty, Prabhat Bhargava, Sujay Srinivas, Vikas Ostwal, Vijay Patil, Vanita Noronha, Suyash Kulkarni, Siddharth Laskar, Kumar Prabhash, Girish Chinnaswamy, Sudeep Gupta, and Shripad Banavali
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
PURPOSEDesmoid fibromatosis (DF) is a locally aggressive tumor with low mortality but significant morbidity. There is a lack of standard of care, and existing therapies are associated with significant barriers including access, cost, and toxicities. This study aimed to explore the efficacy and safety of the metronomic therapy (MT) in DF in a large, homogenous cohort from India.PATIENTS AND METHODSThis study involved histologically confirmed DF cases treated with MT comprising vinblastine (6 mg) and methotrexate (15 mg) both once a week, and tamoxifen (40 mg/m2) in two divided doses once daily between 2002 and 2018.RESULTSThere were 315 patients with a median age of 27 years; the commonest site was extremity (142 of 315; 45.0%). There were 159 (50.1%) male patients. Of the 123 (39.0%) prior treated patients, 119 had surgery. Of 315 patients, 263 (83.5%) received treatment at our institute (MT—151, 77—local treatment, 9—tyrosine kinase inhibitor, and 26 were observed). Among the MT cohort (n = 163, 61.2%), at a median follow-up of 36 (0.5-186) months, the 3-year progression-free and overall survival were 81.1% (95% CI, 74.3 to 88.4) and 99.2% (95% CI, 97.6 to 100), respectively. There were 35% partial responses. Ninety-two patients (56.4%) completed 1-year therapy, which was an independent prognosticator (P < .0001; hazard ratio, 0.177 [95% CI, 0.083 to 0.377]). MT was well tolerated. Predominant grade ≥3 toxicities were febrile neutropenia, 12 (7.4%) without any chemotoxicity-related death. The annual cost of MT was $130 US dollars.CONCLUSIONThe novel, low-cost MT qualifies as one of the effective, less toxic, sustainable, standard-of-care options for the treatment of DF with global reach and merits wide recognition.
- Published
- 2024
- Full Text
- View/download PDF
5. Response Assessment of Treated Hepatocellular Carcinoma
- Author
-
Amitkumar J. Choudhari, Suyash Kulkarni, Nitin Sudhakar Shetty, Kunal Gala, Daksh Chandra, and Akshay D. Baheti
- Subjects
HCC ,LR-TRA ,mRECIST ,response ,Internal medicine ,RC31-1245 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality worldwide, including in India. The incidence of HCC has been rising due to lifestyle diseases such as obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD), as well as viral hepatitis infections. Various locoregional therapies (LRTs) are used to treat HCC, including thermal ablation, transarterial therapies, stereotactic body radiotherapy (SBRT), and transarterial radioembolization (TARE). Traditional response evaluation criteria like WHO and RECIST, which rely on size-based measurements, may not accurately assess treatment response to LRTs. To address this limitation, modified response evaluation criteria for solid tumors (mRECIST) and the LI-RADS treatment response algorithm (LR-TRA) have been developed. mRECIST assesses patient-level response, while LR-TRA provides lesion-level response assessment specifically for HCC treated with LRTs. This article discusses the imaging protocols for diagnosing HCC and the imaging appearances of treated lesions after different LRTs. It explains the criteria for categorizing treatment response, such as LR-TR viable, LR-TR non-viable, and LR-TR equivocal. It also highlights the challenges and future directions in response assessment, including the incorporation of ancillary findings, the assessment of patients receiving a combination of locoregional and systemic therapies, and the potential use of biomarkers like serum AFP, AFP-L3, and PIVKA-II. In conclusion, locoregional therapies have expanded the treatment options for HCC, and accurate response assessment is crucial for optimizing patient management. mRECIST and LR-TRA provide valuable tools for evaluating treatment response, and future updates are expected to address specific challenges and incorporate newer approaches like iRECIST and quantitative imaging assessment. Additionally, the use of biomarkers may complement imaging-based response assessment in the future.
- Published
- 2023
- Full Text
- View/download PDF
6. Endovascular Management of Postoperative Hemorrhage after Pancreaticoduodenectomy
- Author
-
Mohd Shariq, Kunal Gala, Aditi Gandhi, and Rozil Gandhi
- Subjects
endovascular ,gastroduodenal artery ,interventional radiology ,postpancreaticoduodenectomy hemorrhage ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Objective The aim of the study was to assess the safety and efficacy of endovascular management for postpancreaticoduodenectomy hemorrhage.
- Published
- 2023
- Full Text
- View/download PDF
7. Ultrasound-guided assessment of gastric residual volume in patients receiving three types of clear fluids: A randomised blinded study
- Author
-
Jeson Rajan Doctor, Pramila Chandan, Nitin Shetty, Kunal Gala, and Priya Ranganathan
- Subjects
anaesthesiologists ,pyloric antrum ,radiologists ,residual volume ,ultrasonography ,Anesthesiology ,RD78.3-87.3 - Abstract
Background and Aims: Ultrasonography (USG) is used to evaluate gastric residual volume (GRV); however, this technique may have inter-assessor variability. This study aimed to measure GRV in three groups of fasted patients 2 h after they received 200 mL of water, clear apple juice or apple-flavoured oral rehydration solution (ORS) and to determine inter-assessor reliability of USG-guided GRV measurement. Methods: We randomised 90 adult patients planned for elective cancer surgery, with no risk factors for delayed gastric emptying, to receive 200 mL of water, clear apple juice or apple-flavoured ORS after overnight fasting. Two hours later, two blinded assessors (a trained anaesthesiologist and a radiologist) independently determined USG-guided GRV. The primary outcome was GRV measured by the radiologist. The secondary outcome was inter-assessor correlation and agreement in GRV measurements. Results: There was no statistically significant difference in median GRV between groups (apple-flavoured ORS 74.8 mL, apple juice 63.7 mL, and water 62.1 mL, P = 0.11). We found poor correlation between measurements of radiologist and anaesthesiologist (Intra-class correlation coefficient 0.3, 95% confidence intervals 0.09 to 0.48, P value 0.002). The average (mean) bias was 5.4 mL (standard deviation 42.3 mL) and the 95% limits of agreement were -79.2 ml to +90 ml. Conclusion: Patients receiving 200 mL of water, clear apple juice or apple-flavoured ORS had comparable GRV after 2 h. There was poor correlation and agreement between GRV measurements of different assessors, indicating that more training may be required for anaesthesiologists to attain proficiency in the quantitative assessment of GRV.
- Published
- 2021
- Full Text
- View/download PDF
8. Continuous erector spinae plane block in pediatric patients with intraspinal tumors – Case reports
- Author
-
Sumitra G Bakshi, Shilpa Awaskar, Sajid S Qureshi, and Kunal Gala
- Subjects
Anesthesiology ,RD78.3-87.3 ,Pharmacy and materia medica ,RS1-441 - Published
- 2020
- Full Text
- View/download PDF
9. Central venous catheterization in a patient with double right internal jugular vein and persistent left-sided superior vena cava draining into the left atrium
- Author
-
Sohan Lal Solanki, Mihika J Divatia, Kunal Gala, and Jigeeshu V Divatia
- Subjects
Anesthesiology ,RD78.3-87.3 - Published
- 2022
- Full Text
- View/download PDF
10. Interventional radiology preparedness during coronavirus disease (COVID-19) pandemic
- Author
-
Tushar Garg, Ajinkya Desai, Kunal Gala, Gireesh Warawdekar, and Sidhartha Tavri
- Subjects
covid-19 ,interventional radiology ,pandemic ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
The COVID-19 pandemic has affected every sector of healthcare. Interventional Radiology in many instances continues to provide frontline care during this pandemic. The purpose of this article is to assist Interventional Radiologists in their preparation to face the challenges, by summarizing global experiences and guidelines. We provide a basic framework that can be used to prepare institue specific guidelines in coordination with multidisciplinary teams and hospital administration.
- Published
- 2021
- Full Text
- View/download PDF
11. Superficial CD34-positive fibroblastic tumor in the forearm of a middle-aged patient: A newly described, rare soft-tissue tumor
- Author
-
Bharat Rekhi, Devmalya Banerjee, Kunal Gala, and Ashish Gulia
- Subjects
CD34 ,myxoinflammatory fibroblastic sarcoma ,newly described soft-tissue tumors ,superficial CD34-positive fibroblastic tumor ,Pathology ,RB1-214 ,Microbiology ,QR1-502 - Abstract
Superficial CD34-positive fibroblastic tumor is a recently described soft-tissue tumor entity. A 48 year-old-male presented with a gradually increasing soft-tissue mass in his right forearm of 2 years' duration, along with multiple subcutaneous soft-tissue nodular lesions, and reminiscent of lipomas over his body. He underwent a wide excision of his forearm mass. Microscopic sections showed a circumscribed tumor in the dermis and subcutaneous fat, composed of spindle cells, inflammatory cells, including lymphocytes, plasma cells, and eosinophils, along with interspersed markedly pleomorphic giant cells containing moderate-to-abundant “glassy” cytoplasm, vesicular nuclei, exhibiting prominent nucleoli, and intranuclear pseudoinclusions. There were no significant mitotic figures, areas of hemorrhage, necrosis, or pigment histiocytes. By immunohistochemistry, the tumor cells were diffusely positive for CD34 while negative for cytokeratin (CK), pan CK (AE1/AE3), S100 protein, CD30, and CD31. MIB1/Ki-67 was low and highlighted 4%–5% tumor nuclei. Diagnosis of superficial CD34-positive fibroblastic tumor was offered. Sections from the various resection margins were free of tumor. Postresection, the patient is alive with no evidence of disease for the past 8 months. This constitutes as one of the first case reports of this rare tumor entity from our country. Its diagnostic and treatment implications are discussed herewith.
- Published
- 2018
- Full Text
- View/download PDF
12. Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India
- Author
-
Suyash Kulkarni, Nitin S Shetty, Ashwin M Polnaya, Sushil Patil, Kunal Gala, Rahul Chivate, Vikas Ostwal, Anant Ramaswamy, Shailesh V Shrikhande, Mahesh Goel, Shraddha Patkar, Manish Bhandare, Venkatesh Rangarajan, and Purandare Nilendu
- Subjects
radiofrequency ablation ,unresectable colorectal liver metastases ,metastatic colorectal cancer ,liver radiofrequency ablation ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Aims: The study was carried out to evaluate the early outcomes using Radiofrequency Ablation (RFA) for unresectable liver metastases in the management of metastatic colorectal cancer (mCRC) from an area of low endemicity. Material and Methods: 60 Patients with unresectable colorectal liver metastases had undergone 88 sessions of RFA from January 2007 till December 2013. The results were retrospectively analysed to evaluate the outcomes in terms of efficacy and survival rates. Results: The median follow up of patients in our series was 24.8months. 35/52 (67.3%) patients had complete response at 3 months while 8 patients were lost to follow up. Of the 17 patients who had recurrence, 4 (23.5%) were at the ablated site while 13 patients (76.4%) progressed elsewhere. Abdominal pain was commonest post procedural symptom (20%). There was no procedure related mortality or any major complications. Mean disease free interval and Progression free survival was 6.7 and 13.1 months. Estimated median survival in patients with liver limited disease and those with small lesion (3 cm was associated with decreased survival.
- Published
- 2017
- Full Text
- View/download PDF
13. Evaluation and Management of Unresectable Hepatocellular Carcinoma: Multidisciplinary Indian Consensus Statements from a Delphi Panel
- Author
-
Anant Ramaswamy, Akash Shukla, Reena Engineer, Sridhar Sundaram, Sujay Srinivas, Suyash Kulkarni, Shraddha Patkar, Sanjay Baijal, Aditya Kale, Akhil Kapoor, Amar Mukund, Amit Choudhari, Amit Rauthan, Ashwathy Susan Mathew, Rushi Panchal, Kausik Bhattacharya, Prachi Patil, Nitin Shetty, Kunal Gala, Lijesh Kumar, Deepashree Thiruchunapalli, Naveen Kalra, Tarini Prasad Sahoo, M Vamshi Krishna, Viraj Lavingia, Ravi Mohanka, Vineet Talwar, Vikas Ostwal, Prabhat Bhargava, Jyoti Poddar, Amit Singal, and Mahesh Goel
- Subjects
HCC ,hepatocellular carcinoma ,Indian consensus ,MDT ,multidisciplinary tumor board ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Full Text
- View/download PDF
14. Imaging Recommendations for Diagnosis, Staging, and Management of Penile Cancer
- Author
-
Rachel Sequeira, Aparna Katdare, Palak Popat, Nilesh Sable, Kunal Gala, Daksh Chandra, Archi Agrawal, Gagan Prakash, Vedang Murthy, Santosh Menon, Amit Joshi, Ajaykumar Singh, and Suyash Kulkarni
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health - Abstract
Penile cancer is more common in developing countries and presents unique challenges in treatment, given the psychological impact of surgical treatment options on patients. While clinical assessment of the lesions and nodal disease is critical, imaging does play a role in initial staging, response assessment, and surveillance. This article aims to delineate the guidelines for clinical and radiological evaluation of penile cancers and the approach to disease management.
- Published
- 2023
15. Imaging Recommendations for Diagnosis, Staging, and Management of Testicular Cancer
- Author
-
Aparna Katdare, Palak Popat, Rachel Sequeira, Nilesh Sable, Kunal Gala, Daksh Chandra, Archi Agrawal, Gagan Prakash, Vedang Murthy, Santosh Menon, Amit Joshi, Ajaykumar Singh, and Suyash Kulkarni
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health - Abstract
The common testicular tumors affect young males in the third and fourth decades and germ cell tumors especially have excellent post-treatment outcomes. Hence, guidelines for clinical, radiological, and tumor marker assessment for diagnosis, response assessment, and surveillance of these tumors have critical impact on the management of these tumors. This article aims to discuss the current recommendations and guidelines regarding the clinical and radiological assessment and treatment pathways of testicular tumors.
- Published
- 2023
16. Imaging Recommendations for Diagnosis, Staging, and Management of Breast Cancer
- Author
-
Meenakshi Thakur, Suma Chakrabarthi, Purvi Haria, Smriti Hari, Palak Popat, Aparna Katdare, Kunal Gala, Sonal Chouhan, Nita Nair, Jyoti Bajpai, Rima Pathak, Tanuja Shet, Gauravi Mishra, Sneha Shah, Shalaka Joshi, Soujanya Mynalli, Anne Srikanth, and Suyash Kulkarni
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health - Abstract
In a rapidly evolving world, with a steep rise in breast cancer incidence, there has been many advances in imaging and therapeutic options of breast cancer care. In this review article, we are trying to cover imaging guideline for cancer detection and their therapeutic options. These help in the reduction of morbidity and mortality.
- Published
- 2023
17. Imaging Recommendations for Diagnosis, Staging, and Management of Cervical Cancer
- Author
-
Palak Bhavesh Popat, Amita Maheshwari, Smita Manchanda, Rupa Renganathan, Saugata Sen, Ekta Dhamija, Meenakshi Thakur, Kedar Deodhar, Supriya Chopra, Aditya Pavan Kumar Kanteti, Jaya Ghosh, Sneha Shah, Nilesh Sable, Akshay Baheti, Sonal Chauhan, Kunal Gala, and Suyash Kulkarni
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health - Abstract
Cervical cancer is the fourth most common cancer in women globally and the second most common cancer in Indian women, more common in lower socioeconomic strata. Improvement in survival and decrease in morbidity reflect the earlier detection with screening and imaging, as well as multifactorial multimodality therapy integrating surgery, and concurrent chemoradiation therapy providing superior therapeutic benefits. Imaging plays a vital role in assessing the extent of disease and staging of cervical cancer. The appropriateness criteria of a modality are different from its availability based on infrastructure, medical facilities, and resource status. Although in an ideal situation, magnetic resonance imaging (MRI) would be of greatest value in locoregional assessment of extent of disease and fluorodeoxyglucose positron emission tomography-computed tomography for distant staging; often, an ultrasonography, chest radiograph, and bone scans are utilized, with contrast-enhanced computed tomography representing a fair superior diagnostic accuracy, and can be reported as per the RECIST 1.1 criteria. MRI is also of good utility in the assessment of residual disease, predicting response and detecting small volume recurrence. MRI offers the highest diagnostic accuracy in determining parametrial invasion and hence surgical planning; so also, MRI-guided radiation planning helps in more accurate graded radiation dose planning in radiation therapy. Stage and therapy-based surveillance imaging should be encouraged and recommended.
- Published
- 2023
18. Imaging Recommendations for Diagnosis, Staging, and Management of Pancreatic Cancer
- Author
-
Nitin Sudhakar Shetty, Ujjwal Agarwal, Amit Choudhari, Anurag Gupta, Nandakumar PG, Manish Bhandare, Kunal Gala, Daksh Chandra, Anant Ramaswamy, Vikas Ostwal, Shailesh V. Shrikhande, and Suyash S. Kulkarni
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health - Abstract
Pancreatic cancer is the fourth most prevalent cause of cancer-related death worldwide, with a fatality rate equal to its incidence rate. Pancreatic cancer is a rare malignancy with a global incidence and death ranking of 14th and 7th, respectively. Pancreatic cancer cases are divided into three categories without metastatic disease: resectable, borderline resectable, or locally advanced disease. The category is determined by the tumor's location in the pancreas and whether it is abutting or encasing the adjacent arteries and/or vein/s.The stage of disease and the location of the primary tumor determine the clinical presentation: the pancreatic head, neck, or uncinate process, the body or tail, or multifocal disease. Imaging plays a crucial role in the diagnosis and follow-up of pancreatic cancers. Various imaging modalities available for pancreatic imaging are ultrasonography (USG), contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI), and 18-fluoro-deoxy glucose positron emission tomography (FDG PET).Even though surgical resection is possible in both resectable and borderline resectable non-metastatic cases, neoadjuvant chemotherapy with or without radiotherapy has become the standard practice for borderline resectable cases as it gives a high yield of R0 resection.
- Published
- 2023
19. Imaging of central nervous system emergencies in oncology
- Author
-
Kajari Bhattacharya, Kunal Nigam, Amit Kumar J. Choudhari, Nitin Sudhakar Shetty, Kunal Gala, Daksh Chandra, and Suyash Kulkarni
- Subjects
Emergency Medicine ,Radiology, Nuclear Medicine and imaging - Published
- 2023
20. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk‐stratified approach
- Author
-
Shyam Srinivasan, Maya Prasad, Badira C. Parambil, Anurag Shrimal, Venkata Rama Mohan Gollamudi, Vignesh Subramani, Mukta Ramadwar, Nehal Khanna, Akshay D Baheti, Kunal Gala, Vasundhara Patil, Siddhartha Laskar, Sajid Qureshi, and Girish Chinnaswamy
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health ,Hematology - Published
- 2023
21. Leiomyosarcoma of inferior vena cava (IVC): do we really need to reconstruct IVC post resection? Single institution experience
- Author
-
Mahesh Goel, Anand Mohan, Shraddha Patkar, Kunal Gala, Nitin Shetty, Suyash Kulkarni, and Jayesh Dhareshwar
- Subjects
Leiomyosarcoma ,Treatment Outcome ,Humans ,Vena Cava, Inferior ,Surgery ,Retroperitoneal Neoplasms ,Vascular Neoplasms ,Retrospective Studies - Abstract
Inferior vena cava (IVC) leiomyosarcomas (LMS) are a rare group of retroperitoneal tumors. R0 surgical resection is the only curative modality of treatment. IVC resection for retroperitoneal sarcoma is a complex surgery with no definitive guidelines for reconstruction.Retrospective review of all patients who underwent surgical resection of primary leiomyosarcoma of the IVC requiring resection from 2010 to 2020 at our tertiary care center was performed.Among 24 patients who required IVC resection for LMS, only 7 (29%) required reconstruction of IVC. According to Clavien-Dindo classification, there was one grade 3 or more morbidity and 1 post-operative mortality. Seventeen patients underwent R0 resection whereas 7 patients had R1 resection on final histopathology. At a median follow-up of 25 months (range 8-91 months), the median OS was 40 months with median DFS of 28 months. Two patients presented with local recurrence while 13 patients developed systemic recurrence on follow-up.Careful preoperative multidisciplinary planning can make IVC resection without reconstruction feasible with acceptable perioperative morbidity, mortality, and oncological outcomes for IVC LMS.
- Published
- 2022
22. Percutaneous Radiofrequency Ablation of Appendicular Skeleton Chondroblastoma—an Experience from a Tertiary Care Cancer Center
- Author
-
Ashwin Polnaya, Ashish Gulia, Ajay Puri, Mohd Shariq, Suyash Kulkarni, Kunal Gala, Amitkumar Choudhari, Neeraj G. Shetty, Nitin Shetty, and Amit Janu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Percutaneous ,Adolescent ,Radiofrequency ablation ,Appendicular skeleton ,medicine.medical_treatment ,Bone Neoplasms ,Chondroblastoma ,Radiography, Interventional ,030218 nuclear medicine & medical imaging ,law.invention ,Tertiary Care Centers ,Young Adult ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,law ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Acromion ,Child ,Retrospective Studies ,Radiofrequency Ablation ,business.industry ,Cancer ,Ablation ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Lunate ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Feasibility Studies ,Female ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business - Abstract
PURPOSE To evaluate safety and long-term efficacy of radiofrequency (RF) ablation in treatment of chondroblastoma. MATERIALS AND METHODS This retrospective analysis comprised 27 consecutive patients with histopathologically proven chondroblastoma treated by RF ablation. The tumors were located in the proximal humerus (n = 6), proximal tibia (n = 8), proximal femur (n = 6), distal femur (n = 5), acromion process (n = 1), and lunate (n = 1). In 19 patients (70.3%), the tumor was in the weight-bearing area of the bone. Clinical response was assessed by comparing pain scores and functional assessment by Musculoskeletal Tumor Society (MSTS) score before and after ablation. Patients were followed for a minimum of 1 year to rule out complications and recurrence. RESULTS Technical success rate was 100%. Mean pain score before the procedure was 7.34 (range, 7-9); all patients experienced a reduction in pain, with 25 (92.6%) patients reporting complete pain relief at 6 weeks. Mean MSTS score before the procedure was 15.4, whereas mean MSTS score at 6 weeks after the procedure was 28.6, suggesting significant functional improvement (P < .0001). Two patients developed osteonecrosis and collapse of the treated bone. There were no recurrences. CONCLUSIONS Percutaneous RF ablation is a safe and effective option for treating chondroblastoma of the appendicular skeleton.
- Published
- 2021
23. Aortic Fistulas: Pathophysiologic Features, Imaging Findings, and Diagnostic Pitfalls
- Author
-
Maansi Parekh, Harit Kapoor, Aishwarya Gulati, Kunal Gala, and Achala Donuru
- Subjects
musculoskeletal diseases ,Vascular Fistula ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,MEDLINE ,Aortic Diseases ,Multidetector ct ,Aneurysm ,Pathophysiology ,Angiography ,cardiovascular system ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiology ,business ,Tomography, X-Ray Computed ,Vascular Surgical Procedures ,High potential - Abstract
Fistulas between the aorta and surrounding organs are extremely rare but can be fatal if they are not identified and treated promptly. Most of these fistulas are associated with a history of trauma or vascular intervention. However, spontaneous aortic fistulas (AoFs) can develop in patients with weakened vasculature, which can be due to advanced atherosclerotic disease, collagen-vascular disease, vasculitides, and/or hematogenous infections. The clinical features of AoFs are often nonspecific, with patients presenting with bleeding manifestations, back or abdominal pain, fever, and shock. Confirmation with invasive endoscopy is often impractical in the acute setting. Imaging plays an important role in the management of AoFs, and multiphasic multidetector CT angiography is the initial imaging examination of choice. Obvious signs of AoF include intravenous contrast material extravasation into the fistulizing hollow organ, tract visualization, and aortic graft migration into the adjacent structure. However, nonspecific indirect signs such as loss of fat planes and ectopic foci of gas are seen more commonly. These indirect signs can be confused with other entities such as infection and postoperative changes. Management may involve complex and staged surgical procedures, depending on the patient's clinical status, site of the fistula, presence of infection, and anticipated tissue friability. As endovascular interventions become more common, radiologists will need to have a high index of suspicion for this entity in patients who have a history of aneurysms, vascular repair, or trauma and present with bleeding.
- Published
- 2021
24. Interventional radiology preparedness during coronavirus disease (COVID-19) pandemic
- Author
-
Ajinkya Desai, Kunal Gala, Tushar Garg, Gireesh Warawdekar, and Sidhartha Tavri
- Subjects
Coronavirus disease 2019 (COVID-19) ,medicine.diagnostic_test ,business.industry ,pandemic ,R895-920 ,Interventional radiology ,Disease ,Review Article ,030204 cardiovascular system & hematology ,medicine.disease ,030218 nuclear medicine & medical imaging ,Health administration ,03 medical and health sciences ,Medical physics. Medical radiology. Nuclear medicine ,0302 clinical medicine ,covid-19 ,Multidisciplinary approach ,Preparedness ,Health care ,Pandemic ,interventional radiology ,Medicine ,Radiology, Nuclear Medicine and imaging ,Medical emergency ,business - Abstract
The COVID-19 pandemic has affected every sector of healthcare. Interventional Radiology in many instances continues to provide frontline care during this pandemic. The purpose of this article is to assist Interventional Radiologists in their preparation to face the challenges, by summarizing global experiences and guidelines. We provide a basic framework that can be used to prepare institue specific guidelines in coordination with multidisciplinary teams and hospital administration.
- Published
- 2021
25. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization
- Author
-
Vikas Ostwal, Shraddha Patkar, Nitin Shetty, Venkatesh Rangarajan, Suyash Kulkarni, Anant Ramaswamy, Ameya D Puranik, Mahesh Goel, Nilendu Purandare, Atul Yashwant Gosavi, Shailesh V. Shrikhande, Archi Agrawal, Sneha Shah, Kunal Gala, and Ashish Mohite
- Subjects
Adult ,Male ,Carcinoma, Hepatocellular ,Tare weight ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Stage (cooking) ,Survival analysis ,Aged ,Neoplasm Staging ,Retrospective Studies ,Univariate analysis ,Receiver operating characteristic ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Embolization, Therapeutic ,Positron emission tomography ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,Liver cancer ,Nuclear medicine ,business - Abstract
Objective Patients with inoperable multilobar hepatocellular carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) stage B, who have failed other liver-directed treatment options, are ideal candidates for transarterial radioembolization (TARE) with Yttrium-90 (Y-90)-labeled glass spheres. There is limited data regarding variables that impact the prognosis and outcome in these patients. 99mTc-MAA scan for lung shunt fraction (LSF) and 18F-FDG PET/CT are performed during initial workup. We, therefore, decided to assess the prognostic impact of LSF and metabolic parameters, such as maximum SUVmax, MTV and TLG in patients undergoing TARE for HCC. Methods We retrospectively analyzed 64 patients of HCC, between January 2010 and December 2016, deemed suitable for TARE. Pre-TARE LSF was computed on 99mTc MAA scan, and SUVmax, MTV and TLG on fluoro-deoxyglucose positron emission tomography/computed tomography were measured using automated software by 3D region of interest. LSF and PET parameters were stratified using optimal cut-offs derived from receiver operating curve analysis. Survival curves for the groups were estimated using the Kaplan-Meier method and were compared using log-rank test. Results Overall survival (OS) was 15 months. In univariate analysis, high LSF (greater than 7.19), MTV and TLG were statistically significant and were associated with poor OS. In multivariate analysis, TLG (P value 0.044), MTV (P value 0.290) and LSF (P value 0.010) were independent predictors of outcome, after adjustment for significant univariate variables. However, SUVmax was not statistically significant for OS. Conclusions LSF, MTV and TLG are significant independent prognostic indicators of outcome in patients undergoing TARE for HCC.
- Published
- 2020
26. Ultrasound-guided assessment of gastric residual volume in patients receiving three types of clear fluids: A randomised blinded study
- Author
-
Pramila Chandan, Kunal Gala, Jeson R Doctor, Priya Ranganathan, and Nitin Shetty
- Subjects
pyloric antrum ,Gastric emptying ,business.industry ,Clear fluids ,education ,residual volume ,ultrasonography ,Confidence interval ,Ultrasound guided ,Anesthesiology and Pain Medicine ,Anesthesiology ,Anesthesia ,anaesthesiologists ,Medicine ,Original Article ,RD78.3-87.3 ,In patient ,radiologists ,Ultrasonography ,business ,Residual volume ,Blinded study - Abstract
Background and Aims: Ultrasonography (USG) is used to evaluate gastric residual volume (GRV); however, this technique may have inter-assessor variability. This study aimed to measure GRV in three groups of fasted patients 2 h after they received 200 mL of water, clear apple juice or apple-flavoured oral rehydration solution (ORS) and to determine inter-assessor reliability of USG-guided GRV measurement. Methods: We randomised 90 adult patients planned for elective cancer surgery, with no risk factors for delayed gastric emptying, to receive 200 mL of water, clear apple juice or apple-flavoured ORS after overnight fasting. Two hours later, two blinded assessors (a trained anaesthesiologist and a radiologist) independently determined USG-guided GRV. The primary outcome was GRV measured by the radiologist. The secondary outcome was inter-assessor correlation and agreement in GRV measurements. Results: There was no statistically significant difference in median GRV between groups (apple-flavoured ORS 74.8 mL, apple juice 63.7 mL, and water 62.1 mL, P = 0.11). We found poor correlation between measurements of radiologist and anaesthesiologist (Intra-class correlation coefficient 0.3, 95% confidence intervals 0.09 to 0.48, P value 0.002). The average (mean) bias was 5.4 mL (standard deviation 42.3 mL) and the 95% limits of agreement were -79.2 ml to +90 ml. Conclusion: Patients receiving 200 mL of water, clear apple juice or apple-flavoured ORS had comparable GRV after 2 h. There was poor correlation and agreement between GRV measurements of different assessors, indicating that more training may be required for anaesthesiologists to attain proficiency in the quantitative assessment of GRV.
- Published
- 2020
27. Are radiological diagnostic centres ready to tackle COVID-19 pandemic? An Indian perspective
- Author
-
Kunal Gala, Foram B Gala, and Bharat M. Gala
- Subjects
Coronavirus disease 2019 (COVID-19) ,business.industry ,Transmission (medicine) ,Social distance ,R895-920 ,COVID-19 ,Disease ,Review Article ,medicine.disease ,health care workers ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Medical physics. Medical radiology. Nuclear medicine ,0302 clinical medicine ,diagnostic centers ,Radiological weapon ,Preparedness ,Health care ,Pandemic ,Medicine ,Radiology, Nuclear Medicine and imaging ,Medical emergency ,business ,030217 neurology & neurosurgery - Abstract
Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) and has been declared as pandemic. Its transmission is mainly by droplets and touching infected surfaces. Health care workers including personnel working at diagnostic centers are more prone to contact the disease through infected patients and hence various precautionary measures have to be implemented which has been discussed in this article. This manuscript shall brief about the preparedness by the diagnostic center in terms of the modification in the work flow, the precautions and protections to be taken by the personnel and patients, disinfection of the equipment and surfaces, and new norms of social distancing. This article will be addressing mainly to the diagnostic centers and the changes to be made as per their convenience.
- Published
- 2020
28. Continuous erector spinae plane block in pediatric patients with intraspinal tumors - Case reports
- Author
-
Sajid S. Qureshi, Kunal Gala, Sumitra G Bakshi, and Shilpa Awaskar
- Subjects
Orthodontics ,business.industry ,lcsh:RS1-441 ,Plane (Unicode) ,lcsh:RD78.3-87.3 ,lcsh:Pharmacy and materia medica ,Anesthesiology and Pain Medicine ,lcsh:Anesthesiology ,Block (telecommunications) ,Medicine ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,business ,Letters to Editor - Published
- 2020
29. Central venous catheterization in a patient with double right internal jugular vein and persistent left-sided superior vena cava draining into the left atrium
- Author
-
SohanLal Solanki, MihikaJ Divatia, Kunal Gala, and JigeeshuV Divatia
- Subjects
Anesthesiology and Pain Medicine - Published
- 2022
30. Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India
- Author
-
Kunal Gala, Sushil Patil, Shraddha Patkar, Suyash Kulkarni, Vikas Ostwal, Venkatesh Rangarajan, Mahesh Goel, Shailesh V. Shrikhande, Rahul Chivate, Purandare Nilendu, Ashwin Polnaya, Manish S. Bhandare, Anant Ramaswamy, and Nitin Shetty
- Subjects
Abdominal pain ,medicine.medical_specialty ,unresectable colorectal liver metastases ,business.industry ,Colorectal cancer ,Radiofrequency ablation ,metastatic colorectal cancer ,R895-920 ,Cancer ,medicine.disease ,law.invention ,Surgery ,Medical physics. Medical radiology. Nuclear medicine ,Median follow-up ,law ,Intervention Radiology & Vascular ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,radiofrequency ablation ,Progression-free survival ,Lost to follow-up ,medicine.symptom ,business ,liver radiofrequency ablation - Abstract
Aims: The study was carried out to evaluate the early outcomes using Radiofrequency Ablation (RFA) for unresectable liver metastases in the management of metastatic colorectal cancer (mCRC) from an area of low endemicity. Material and Methods: 60 Patients with unresectable colorectal liver metastases had undergone 88 sessions of RFA from January 2007 till December 2013. The results were retrospectively analysed to evaluate the outcomes in terms of efficacy and survival rates. Results: The median follow up of patients in our series was 24.8months. 35/52 (67.3%) patients had complete response at 3 months while 8 patients were lost to follow up. Of the 17 patients who had recurrence, 4 (23.5%) were at the ablated site while 13 patients (76.4%) progressed elsewhere. Abdominal pain was commonest post procedural symptom (20%). There was no procedure related mortality or any major complications. Mean disease free interval and Progression free survival was 6.7 and 13.1 months. Estimated median survival in patients with liver limited disease and those with small lesion (3 cm was associated with decreased survival.
- Published
- 2017
31. Abstract No. 561 Percutaneous endoluminal brush cytology in patients suspected of malignant biliary obstruction: Experience from a tertiary cancer center in India
- Author
-
Suyash Kulkarni, Ashwin Polnaya, I. Salroo, N. Purandare, Sushil Patil, Mukta Ramadwar, Kunal Gala, S.V. Shrikhande, M. Goel, R. Gandhi, and Nitin Shetty
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,Brush cytology ,Medicine ,Cancer ,Radiology, Nuclear Medicine and imaging ,In patient ,Center (algebra and category theory) ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease - Published
- 2018
32. 3:45 PM Abstract No. 257 Role of radiofrequency ablation as a salvage treatment for recurrent fibromatosis: retrospective analysis
- Author
-
Suyash Kulkarni, Ashwin Polnaya, R. Chivate, Kunal Gala, P. Patel, and Nitin Shetty
- Subjects
medicine.medical_specialty ,business.industry ,Radiofrequency ablation ,law ,Salvage treatment ,medicine ,Retrospective analysis ,Radiology, Nuclear Medicine and imaging ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Recurrent fibromatosis ,law.invention - Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.